Neurogene (NGNE) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
November 19, 2024 4:02 PM ESTBMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ: NGNE) to $45.00 (from $60.00) while maintaining a Outperform rating.
The analyst comments "Neurogene shares are trading near cash on: 1) emerging SAE in a high-dose patient, consistent with overexposure/overdose of AAV9 or adenovirus... More
